Skip to main content

Viridian Therapeutics, Inc.

VRDN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001590750

In the last 90 days, Viridian Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 214 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.

Superinvestors holding VRDN, Q2 2026

See all superinvestors

No superinvestor reported holding VRDN in Q2 2026.

Moves by quarter

Superinvestors that opened, added to, trimmed or sold out of VRDN each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.

  1. Q4 2025

    0 superinvestors holding at quarter end

    Sold out
    Maverick Capital
  2. Q3 2025

    1 superinvestor holding at quarter end

    Reduced
    Maverick Capital (−2.0%)
  3. Q2 2025

    1 superinvestor holding at quarter end

    Added
    Maverick Capital (+9.5%)
  4. Q1 2025

    1 superinvestor holding at quarter end

    Added
    Maverick Capital (+0.4%)
  5. Q4 2024

    1 superinvestor holding at quarter end

    Added
    Maverick Capital (+2.8%)
  6. Q3 2024

    1 superinvestor holding at quarter end

    Reduced
    Maverick Capital (−39.6%)
  7. Q2 2024

    1 superinvestor holding at quarter end

    Added
    Maverick Capital (+22.9%)
  8. Q1 2024

    1 superinvestor holding at quarter end

    Added
    Maverick Capital (+15.8%)
  9. Q4 2023

    1 superinvestor holding at quarter end

    New
    Maverick Capital